TRIAZAVIRIN® registered for the treatment of ARVI in children aged 6 years and older

In September 2025, the Russian Ministry of Health issued a registration certificate for a new dosage form of the broad-spectrum antiviral drug TRIAZAVIRIN® for the treatment of ARVI in school-age children—100 mg.

TRIAZAVIRIN® has a marked antiviral effect: it suppresses the synthesis of RNA-containing viruses and the replication of genomic fragments.

Thus, pediatricians have obtained a new drug for the treatment of ARVI in children that targets the underlying cause of the disease.

See the For Children section for detailed information about the drug.